These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32401060)

  • 1. Rationale for and clinical development of anti-fractalkine antibody in rheumatic diseases.
    Muraoka S; Nishio J; Kuboi Y; Imai T; Nanki T
    Expert Opin Biol Ther; 2020 Nov; 20(11):1309-1319. PubMed ID: 32401060
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases.
    Tanaka Y; Hoshino-Negishi K; Kuboi Y; Tago F; Yasuda N; Imai T
    Immunotargets Ther; 2020; 9():241-253. PubMed ID: 33178636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasma-exchange in the treatment of systemic rheumatic diseases: past and present experience].
    Cozzi F; Marson P
    Reumatismo; 2009; 61(3):161-4. PubMed ID: 19888500
    [No Abstract]   [Full Text] [Related]  

  • 4. Fractalkine/CX3CL1 in rheumatoid arthritis.
    Nanki T; Imai T; Kawai S
    Mod Rheumatol; 2017 May; 27(3):392-397. PubMed ID: 27484962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suspected inflammatory rheumatic diseases in patients presenting with skin rashes.
    Alves F; Gonçalo M
    Best Pract Res Clin Rheumatol; 2019 Aug; 33(4):101440. PubMed ID: 31585842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell depletion in lupus and Sjögren's syndrome: an update.
    Coca A; Sanz I
    Curr Opin Rheumatol; 2009 Sep; 21(5):483-8. PubMed ID: 19644378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus.
    Reichlin M; Fesmire J; Quintero-Del-Rio AI; Wolfson-Reichlin M
    Arthritis Rheum; 2002 Nov; 46(11):2957-63. PubMed ID: 12428237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the fractalkine-CX3CR1 axis ameliorates experimental colitis by dislodging venous crawling monocytes.
    Kuboi Y; Nishimura M; Ikeda W; Nakatani T; Seki Y; Yamaura Y; Ogawa K; Hamaguchi A; Muramoto K; Mizuno K; Ogasawara H; Yamauchi T; Yasuda N; Onodera H; Imai T
    Int Immunol; 2019 Apr; 31(5):287-302. PubMed ID: 30668715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases.
    Rafael-Vidal C; Pérez N; Altabás I; Garcia S; Pego-Reigosa JM
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis.
    Ruth JH; Volin MV; Haines GK; Woodruff DC; Katschke KJ; Woods JM; Park CC; Morel JC; Koch AE
    Arthritis Rheum; 2001 Jul; 44(7):1568-81. PubMed ID: 11465708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-B cell antibody therapies for inflammatory rheumatic diseases.
    Faurschou M; Jayne DR
    Annu Rev Med; 2014; 65():263-78. PubMed ID: 24160940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of fractalkine ameliorates murine collagen-induced arthritis.
    Nanki T; Urasaki Y; Imai T; Nishimura M; Muramoto K; Kubota T; Miyasaka N
    J Immunol; 2004 Dec; 173(11):7010-6. PubMed ID: 15557198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell subsets and their role in the pathogenesis of rheumatic disease.
    Gizinski AM; Fox DA
    Curr Opin Rheumatol; 2014 Mar; 26(2):204-10. PubMed ID: 24445478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recruitment of CD16+ monocytes into synovial tissues is mediated by fractalkine and CX3CR1 in rheumatoid arthritis patients.
    Yano R; Yamamura M; Sunahori K; Takasugi K; Yamana J; Kawashima M; Makino H
    Acta Med Okayama; 2007 Apr; 61(2):89-98. PubMed ID: 17471309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of genetics and epigenetics in rheumatic diseases: are they really a target to be aimed at?
    Kato M; Yasuda S; Atsumi T
    Rheumatol Int; 2018 Aug; 38(8):1333-1338. PubMed ID: 29623390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractalkine stimulates cell growth and increases its expression via NF-κB pathway in RA-FLS.
    Guo X; Pan Y; Xiao C; Wu Y; Cai D; Gu J
    Int J Rheum Dis; 2012 Jun; 15(3):322-9. PubMed ID: 22709495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antinuclear antibody and other immunohematological profiles among primary Sjögren's syndrome, secondary Sjögren's syndrome associated with rheumatoid arthritis or systemic lupus erythematosus, and corresponding systemic disease.
    Ichikawa Y; Takaya M; Shimizu H; Uchiyama M; Moriuchi J; Morita K; Hoshina Y; Horiki T
    Tokai J Exp Clin Med; 1993 Dec; 18(3-6):133-8. PubMed ID: 7701526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depletion for rheumatic diseases: where are we?
    Cohen SB
    MedGenMed; 2005 Jun; 7(2):72. PubMed ID: 16369450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway.
    Imai T; Yasuda N
    Inflamm Regen; 2016; 36():9. PubMed ID: 29259682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients.
    Payet J; Goulvestre C; Bialé L; Avouac J; Wipff J; Job-Deslandre C; Batteux F; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2014 Dec; 41(12):2395-402. PubMed ID: 25274898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.